Hospitals in England have reported shortages of several widely used medicines, including the common painkiller paracetamol, according to reporting by the Guardian published on 5 October. The same report said NHS trusts also experienced disruption last winter to supplies of co-codamol, another pain relief drug, and ramipril, which is used to treat high blood pressure.
The Guardian’s account, based on information from hospital trusts, indicates that the supply problems have affected routine care, as these medicines are standard treatments across wards and clinics. Independent corroboration of the scale and duration of the shortages is limited so far, and the situation may become clearer as more data from the health service is released.
What hospitals are reporting
According to the Guardian, multiple NHS hospital trusts in England have raised concerns about access to basic medicines they rely on daily. Paracetamol, an over-the-counter painkiller that is also stocked in hospital pharmacies in larger, prescription-strength formats, was among the drugs reported to be in short supply.
The same report said that co-codamol, a combination of paracetamol and codeine used for moderate pain, also faced supply disruption. In addition, hospitals reported problems obtaining ramipril, a commonly prescribed angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure and heart conditions.
The Guardian did not specify in detail which individual trusts were affected or provide precise figures on how many hospitals reported shortages, but it described the issue as affecting hospitals across England rather than being confined to a single region.
Medicines involved and why they matter
Paracetamol is one of the most frequently used medicines in hospitals, prescribed for pain and fever in adults and children. Because it is a first-line treatment for many conditions, any disruption to its availability can force clinicians to adjust pain management plans and consider alternative drugs.
Co-codamol is typically used when paracetamol alone is not sufficient. The Guardian’s reporting suggests that disruption to both paracetamol and co-codamol supplies may have reduced the options available to doctors and nurses for managing pain, particularly after surgery or in patients with chronic conditions.
Ramipril is widely used in the management of high blood pressure and heart failure. Hospitals and community services both rely on it, and the Guardian report indicates that hospital trusts specifically noted difficulties obtaining this medicine during the previous winter. While the article did not detail clinical outcomes, interruptions to a drug like ramipril can complicate the routine management of cardiovascular patients.
When the disruption occurred
The Guardian report stated that shortages of paracetamol were affecting hospitals at the time of publication in early October. It also said that NHS trusts had reported disruption last winter to supplies of co-codamol and ramipril.
The reference to last winter suggests the supply problems with co-codamol and ramipril were not limited to a single short-term incident, but the report did not specify exactly when the shortages began or how long they lasted. It also did not confirm whether the earlier disruption has fully resolved, or whether any knock-on effects are still being felt in hospital procurement.
Impact on patient care
The Guardian’s account focuses on the presence of shortages and disruptions rather than detailed clinical consequences. It reports that hospitals were hit by shortages of paracetamol and had experienced disruption to co-codamol and ramipril supplies, but it does not quantify the number of patients affected or describe specific cases where treatment was delayed or changed.
Based on the medicines involved, the immediate impact is likely to have been felt in routine prescribing, pharmacy stock management and ward-level medication rounds. When basic drugs become harder to obtain, hospitals often have to:
- Substitute with alternative medicines where clinically appropriate
- Adjust dosages or treatment plans
- Tighten controls on existing stock to avoid waste
The Guardian report does not provide detailed information on which of these measures were taken in response to the current shortages. It also does not state whether any procedures were cancelled or rescheduled as a direct result.
What remains unclear
Because the current reporting is based primarily on the Guardian’s account, several important questions remain unanswered:
- Scale: The Guardian indicates that hospitals in England have been affected, but it does not provide a count of trusts or beds covered by the shortages.
- Duration: The report notes that disruptions to co-codamol and ramipril occurred last winter, but does not specify whether those issues are ongoing or fully resolved.
- Cause: The article does not identify a confirmed cause for the shortages, such as manufacturing issues, distribution problems or increased demand.
- Official response: The Guardian report, as summarized here, does not detail formal statements from NHS England, the Department of Health and Social Care or regulators on the specific shortages of paracetamol, co-codamol and ramipril.
Independent verification of the scope and drivers of these shortages is limited at this stage. Further information from NHS bodies, regulators or additional hospital trusts would help clarify whether the problems are localised or part of a wider pattern in medicine supply.
Why this matters and what to watch
Shortages of everyday medicines such as paracetamol, co-codamol and ramipril matter because they affect drugs that hospitals use constantly for pain relief and cardiovascular care. When these basic treatments are harder to obtain, it can complicate routine care and put additional pressure on hospital pharmacies and clinical teams.
The Guardian’s reporting highlights that the issue is not limited to rare or highly specialised drugs, but includes medicines that many patients in England will recognise from their own prescriptions. Readers should watch for further statements from NHS England, local trusts and health regulators in the coming weeks, which could provide clearer data on the extent of the shortages, the reasons behind them and any measures being taken to stabilise supplies.
